Collaborative research agreement

Collaborative research agreement

Aciex Therapeutics has entered into a collaborative research agreement with Portola Pharmaceuticals that provides Aciex with exclusive rights to develop Portola’s small molecule dual Spleen Tyrosine Kinase (Syk)/Janus Kinase (JAK) inhibitors for ophthalmic indications. “The Portola library includes both compounds with extensive preclinical systemic data packages as well as earlier stage research compounds. The two companies will target development of drugs to treat topical ophthalmic diseases, including ocular allergy, dry eye and other inflammatory eye conditions, for which there is a strong scientific rationale for Syk and JAK inhibition,†said an Aciex spokeswoman. Under the terms of the agreement, Aciex will obtain access to Portola’s small molecule dual Syk/JAK inhibitors and will lead clinical development activities for ophthalmic indications. Both companies will fund and participate in development activities related to the programmes. Portola retains the right to develop these compounds for nonophthalmic indications.

http://aciexrx.com

Latest Articles
Towards a Unified IOL Classification

The new IOL functional classification needs a strong and unified effort from surgeons, societies, and industry.

Read more...

The 5 Ws of Post-Presbyopic IOL Enhancement

Fine-tuning refractive outcomes to meet patient expectations.

Read more...

AI Shows Promise for Meibography Grading

Study demonstrates accuracy in detecting abnormalities and subtle changes in meibomian glands.

Read more...

Are There Differences Between Male and Female Eyes?

TOGA Session panel underlined the need for more studies on gender differences.

Read more...

Simulating Laser Vision Correction Outcomes

Individualised planning models could reduce ectasia risk and improve outcomes.

Read more...

Mastering IOL Exchange

Tips and tricks for an uncomplicated replacement procedure.

Read more...

Need to Know: Aberrations, Aberrometry, and Aberropia

Understanding the nomenclature and techniques.

Read more...

When Is It Time to Remove a Phakic IOL?

Close monitoring of endothelial cell loss in phakic IOL patients and timely explantation may avoid surgical complications.

Read more...

Delivering Uncompromising Cataract Care

Expert panel considers tips and tricks for cataracts and compromised corneas.

Read more...

Organising for Success

Professional and personal goals drive practice ownership and operational choices.

Read more...